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1. Introduction 
Kidney is one of the most important organs in the regulation of mineral metabolism 
(Fukagawa et al., 2006). Chronic kidney disease (CKD) is a worldwide public health 
problem that affects 5% to 10% of the world population, with increasing prevalence and 
adverse outcomes, including progressive loss of kidney function, cardiovascular disease, 
and premature death (Eknoyan et al., 2004). Calcium and phosphorus are fundamentally 
important in a wide array of biological functions. Abnormalities in calcium, phosphorus, 
parathyroid hormone (PTH), and vitamin D metabolism (usually referred to as disordered 
mineral metabolism) are common in patients with (CKD) (Block et al., 1998). Cardiovascular 
disease is the leading cause of death in patients with CKD (London et al., 2003). It has been 
shown that in individuals with kidney failure on maintenance dialysis who are younger 
than 65 years, cardiovascular mortality is 10 to 500 times higher than in the general 
population, even after adjustment for sex, race, and presence of diabetes (Foley RN et al., 
1998). Disturbances in mineral metabolism are common complications of CKD and an 
important cause of morbidity and decreased quality of life. Importantly, increasing evidence 
suggests that these disturbances are associated with changes in arterial compliance, 
cardiovascular calcification, bone disorders and all-cause and cardiovascular mortality 
(Palmer SC et al., 2005, Drueke et al., 2010). Traditionally, when defining bone diseases in 
CKD patients, this group of disorders has been usually termed renal osteodystrophy. 
However, beside strictly defined, the term renal osteodystrophy means only bone 
abnormalities. Recently, the KDIGO (Kidney Disease: Improving Global Outcomes) 
conference group agreed that the definition of renal osteodystrophy should be only specific 
to bone pathology found in patients with CKD (Moe S. et al., 2006). It has been concluded 
that renal osteodystrophy is one component of the mineral and bone disorders that occur as 
a complication of CKD. It has been proposed that the evaluation and definitive diagnosis of 
renal osteodystrophy requires performing a bone biopsy. Histomorphometry is not essential 
for clinical diagnosis, but should be performed in research studies. There was an agreement 
that histomorphometric results are to be reported by use of the standard nomenclature 
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recommended by the American Society for Bone and Mineral Research (Parfitt et al., 1987), 
and investigators would supply primary measurements used to report any derived 
parameters. Based on all of this a new term has been proposed and coined “Chronic kidney 
disease – mineral and bone disorder (CKD-MBD)” willing to describe the systemic 
consequences of mineral metabolism disturbances in CKD patients which can no longer be 
considered restricted only to bone disease. CKD-MBD defines a triad of interrelated 
abnormalities of serum biochemistry, bone and the vasculature associated with CKD. The 
adverse effects of high serum phosphorus and an increase of serum calcium due to calcium 
overload which are present late in CKD are important component of CKD-MBD as well as 
vascular changes. Furthermore, to clarify the interpretation of bone biopsy results in the 
evaluation of CKD-MBD, it has been proposed to use three key histologic descriptors—bone 
turnover, bone mineralization, and bone volume (so called TMV system)— with any 
combination of each of the descriptors possible in a given specimen. The TMV classification 
scheme provides a clinically relevant description of the underlying bone pathology, as 
assessed by histomorphometry, which, in turn, helps to define the pathophysiology, and, 
thereby, probably to guide the therapy (Moe S. et al., 2006). 
2. CKD – MBD and biochemical abnormalities 
The initial evaluation of CKD-MBD should include laboratory for calcium (it has been 
proposed either ionized or total corrected for albumin), phosphorus, PTH, alkaline 
phosphatases (total or bone specific), bicarbonate, as well as imaging for soft-tissue 
calcification. Epidemiologic studies from the early 1990s have demonstrated that an increase 
in serum phosphorus and in calcium x phosphorus product are associated with poor 
outcomes in CKD patients. The association of elevated serum phosphorus and calcium and 
increased mortality in these patients has been confirmed in several recent studies. If 
inconsistencies exist in the biochemical markers (eg, high PTH but low alkaline 
phosphatases), unexplained bone pain, or unexplained fractures are present, a bone biopsy 
would be strongly indicated (London and Drueke, 1997; London et al., 2003; Neves et al., 
2007; Bucay et al., 1998). 
2.1 Calcium 
Serum calcium is tightly controlled in healthy individuals, within a narrow range, usually 
2.2–2.6 mmol/l, with a minimal, diurnal variation. In patients with CKD, serum calcium 
levels fluctuate more, because of altered homeostasis and concomitant therapies. Serum 
calcium levels are routinely measured in clinical laboratories using colorimetric methods in 
automated machines. In patients with CKD stage 5D, there are additional fluctuations in 
association with dialysis-induced changes, hemoconcentration, and subsequent 
hemodilution. Moreover, predialysis samples collected from dialysis patients after the 
longer interdialytic interval during the weekend, as compared with predialysis samples 
drawn after the shorter interdialytic intervals during the week, often contain higher serum 
calcium levels (Tentori et al., 2008). It has been shown that the serum calcium level is a poor 
reflection of overall total body calcium. Only 1% of total body calcium is measurable in the 
extracellular compartment while the most important part of calcium is stored in the bones. 
Serum ionized calcium, generally 40–50% of total serum calcium, is physiologically active, 
while non-ionized calcium is bound to albumin or anions such as citrate, bicarbonate, and 
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phosphate, and is therefore not physiologically active. In the presence of hypoalbuminemia, 
there is an increase in ionized calcium relative to total calcium; thus, total serum calcium 
may underestimate the physiologically active (ionized) serum calcium. The most commonly 
used formula for estimating ionized calcium from total calcium is the addition of 0.2 mmol/l 
for every 1 g decrease in serum albumin below 40 g/l. Unfortunately, recent data have 
shown that it offers no superiority over total calcium alone and is less specific than ionized 
calcium measurements. In addition, the assay used for albumin may affect the corrected 
calcium measurement.  
2.2 Phosphorus 
It has been shown that inorganic phosphorus is critical for numerous normal physiological 
functions, including skeletal development, mineral metabolism, cell-membrane 
phospholipid content and function, cell signaling, platelet aggregation, and energy transfer 
through mitochondrial metabolism. Owing to its importance, normal homeostasis maintains 
serum concentrations between 0.81–1.45 mmol/l. The terms, phosphorus and phosphate, are 
often used interchangeably, but strictly speaking, the term phosphate means the sum of the 
two physiologically occurring inorganic ions in the serum, and in other body fluids, 
hydrogenphosphate (HPO42) and dihydrogenphosphate (H2PO4). However, most 
laboratories report this measurable, inorganic component as phosphorus. Unlike calcium, a 
major component of phosphorus is intracellular, and factors such as pH and glucose can 
cause shifts of phosphate ions into or out of cells, thereby altering the serum concentration 
without changing the total body phosphorus. Phosphorus is routinely measured in clinical 
laboratories with colorimetric methods in automated machines. Serum phosphorus levels 
reach the lowest level in the early hours of the morning, increasing to a plateau at the 
afternoon, and further increasing to a peak late in the evening (Portale et al., 1987).  
Hyperphosphatemia occurs as a consequence of diminished phosphorus filtration and 
excretion with the progression of CKD. Decreased phosphorus excretion can initially be 
overcome by increased secretion of parathyroid hormone (PTH), which decreases proximal 
phosphate reabsorption (Slatopolsky and Delmez, 1994). Hence, phosphorus levels are 
usually within normal range until the GFR falls below approximately 30 ml/min, or stage 
IV. CKD according to the National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative (NKF–K/DOQI) classification (National Kidney Foundation: K/DOQI). In more 
advanced stages of CKD, the blunted urinary excretion of phosphorus can no longer keep 
pace with the obligatory intestinal phosphate absorption, resulting in hyperphosphatemia. 
Therefore, it is not surprising that the majority of patients with CKD stage 4 and stage 5 
have a significant hyperphosphatemia (Block et al., 1998). It has been shown that in patients 
with advanced CKD high serum calcium, phosphate, and calcium-phosphate product levels 
are associated with unaccountably high rates of cardiovascular disease (Ganesh et al., 2001; 
Stevens et al., 2004; Slinin et al., 2005). Moreover, it has been shown also that these 
derangements in mineral metabolism could occur as well during the early stages of CKD 
(Slatopolsky and Delmez, 1994).  
2.3 Parathyroid hormone 
The parathyroid gland plays an important role in the regulation of mineral homeostasis by 
effects trough other organs such as the kidney and bone. Fluctuation in extracellular calcium 
www.intechopen.com
 
Chronic Kidney Disease 
 
28
ion levels is sensed by the parathyroid calcium-sensing receptors (CaSRs) and subsequently 
regulates the synthesis and secretion of parathyroid hormone (PTH) (Felsenfeld et al., 2007). 
PTH acts on the bone to increase the efflux of calcium and phosphate, and acts on the kidney 
to reduce urinary calcium excretion, inhibit phosphate reabsorption, and stimulate the 
production of 1,25-dihydroxyvitamin D (1,25(OH)2D). PTH is cleaved to an 84-amino-acid 
protein in the parathyroid gland, where it is stored with fragments in secretory granules for 
release. When it is released, the circulating 1–84-amino-acid protein has a half-life of 2–4 min. 
The hormone is cleaved both within the parathyroid gland and after secretion into the N-
terminal, C-terminal, and middle region fragments of PTH, which are metabolized in the liver 
and in the kidneys. Enhanced PTH synthesis/secretion occurs in response to hypocalcemia, 
hyperphosphatemia, and/or a decrease in serum 1,25-dihydroxyvitamin D (1,25(OH)2D), 
whereas high serum levels of calcium or calcitriol—and, as recently shown, of Fibroblast 
growth factor 23 (FGF-23)—suppress PTH synthesis/secretion. The extracellular concentration 
of ionized calcium is the most important determinant of the minute-to-minute secretion of 
PTH, which is normally oscillatory.  
In patients with CKD, this normal oscillation is somehow altered. Over the past few decades 
there has been a progress in development of sensitive assays in order to measure PTH.  
Initial measurements of PTH using C-terminal assays were inaccurate in patients with CKD 
because of the impaired renal excretion of C-terminal fragments (and thus retention) and the 
measurement of these probably inactive fragments. The development of the N-terminal 
assay was initially thought to be more accurate but it also detected inactive metabolites. The 
development of a second generation of PTH assays, the two-site immunoradiometric 
assay—commonly called an ‘intact PTH’ assay—improved the detection of full-length 
(active) PTH molecules. In this assay, a captured antibody binds within the amino terminus 
and a second antibody binds within the carboxy terminus. Unfortunately, recent data 
indicate that this ‘intact’ PTH assay also detects accumulated large C-terminal fragments, 
commonly referred to as ‘7–84’ fragments; these are a mixture of four PTH fragments that 
include, and are similar in size to, 7–84 PTH (Gao and D'Amour 2005). In 
parathyroidectomized rats, the injection of a truly whole 1- to 84-amino-acid PTH was able 
to induce bone resorption, whereas the 7- to 84-amino-acid fragment was antagonistic, 
explaining why patients with CKD may have high levels of ‘intact’ PTH but relative 
hypoparathyroidism at the bone-tissue level (Slatopolsky et al., 2000; Malluche et al., 2003; 
Huan et al., 2006). Thus, the major difficulty in accurately measuring PTH with this assay is 
the presence of circulating fragments, particularly in the presence of CKD. Unfortunately, 
the different assays measure different types and amounts of these circulating fragments, 
leading to inconsistent results. More recently, a third generation of assays has become 
available that truly detect only the 1- to 84-amino-acid, full-length molecule: ‘whole’ or 
‘bioactive’ PTH assays. There are differences in PTH results when samples are measured in 
plasma, serum, or citrate, and depending on whether the samples are on ice, or are allowed 
to sit at room temperature.  
PTH and vitamin D have been shown to influence cardiac and vascular growth and function 
experimentally in human subjects with normal renal function. Because of increased 
prevalence of hyperparathyroidism and altered vitamin D status in CKD, these alterations 
have been considered to contribute to the increased prevalence of cardiovascular disease 
and hypertension seen in this patient population (Slinin Y et al., 2005).  
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2.4 Vitamin D (25(OH)D)  
The parent compounds of vitamin D—D3 (cholecalciferol) or D2 (ergocalciferol)—are highly 
lipophilic. They are difficult to quantify in the serum or plasma. They also have a short half-
life in circulation of about 24 h. These parent compounds are metabolized in the liver to 
25(OH)D3 (calcidiol) or 25(OH)D2 (ercalcidiol). Collectively, they are called 25(OH)D or 25-
hydroxyvitamin D. The measurement of serum 25(OH)D is regarded as the best measure of 
vitamin D status, because of its long half-life of approximately 3 weeks. In addition, it is an 
assessment of the multiple sources of vitamin D, including both nutritional intake and skin 
synthesis of vitamin D. There is a seasonal variation in calcidiol levels because of an increased 
production of cholecalciferol by the action of sunlight on skin during summer months. The 
gold standard of calcidiol measurement is high performance liquid chromatography (HPLC), 
but this is not widely available clinically. This is because HPLC is time consuming, requires 
expertise and special instrumentation, and is expensive. In early 1985, Hollis and Napoli 
developed the first radioimmunoassay (RIA) for total 25(OH)D, which was co-specific for 
25(OH)D2 and 25(OH)D3. The values correlated with those obtained from HPLC analysis, and 
DiaSorin RIA became the first test to be approved by the Food and Drug Administration for 
use in clinical settings (Hollis and Napoli, 1985). Another method now carried out is liquid 
chromatography- tandem mass spectrometry (LC-MS/MS). Similar to HPLC, the LC-MS/MS 
method also has the ability to quantify 25(OH)D2 and 25(OH)D3 separately, which 
distinguishes it from RIA and enzyme-linked immunosorbent assay technologies. This 
method is very accurate and has been shown to correlate well with DiaSorin RIA (Saenger et 
al. 2006; Tsugawa et al., 2005). It has been suggested recently that the assays for 25(OH)D are 
not well standardized, and the definition of deficiency is not yet well validated. At best, 
clinicians should ensure that patients use the same laboratory for measurements of these 
levels, if carried out. The most appropriate vitamin D assays presently available seem to be 
those that measure both 25(OH)D2 and 25(OH)D3. Presently, approximately 20–50% of the 
general population has low vitamin D levels, irrespective of CKD status. However, the 
benefits from replacing vitamin D have not been documented in patients with CKD, 
particularly if they are taking calcitriol or a vitamin D analog.  
2.5 Vitamin D (1,25(OH)2D)  
1,25(OH)2D is used to describe both hydroxylated D2 (ercalcitriol) and D3 (calcitriol) 
compounds, both of which have a short half-life of 4–6 h. Furthermore, in patients with 
earlier stages of CKD and in the general population, mild-to-moderate vitamin D deficiency, 
or partly treated vitamin D deficiency, is frequently associated with increased levels of 
1,25(OH)2D. Thus, even accurate levels can be misleading. The serum levels of 1,25(OH)2D 
are uniformly low in late stages of CKD–MBD, at least in patients not treated with vitamin D 
derivatives (Andress et al., 2006). It has not been recommend a routine measurement of 
1,25(OH)2D levels, as the assays are not well standardized, the half-life is short, and there 
are no data indicating that the measurement is helpful in guiding therapy or predicting 
outcomes (KDIGO).  
2.6 Alkaline phosphatases 
Alkaline phosphatases (ALP) are enzymes that remove phosphate from proteins and 
nucleotides, functioning optimally at alkaline pH. Measurement of the level of total ALP (t-
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ALP) is a colorimetric assay that is routinely used in clinical laboratories in automated 
machines. The enzyme is found throughout the body in the form of isoenzymes that are 
unique to the tissue of origin. Highest concentrations are found in the liver and bone, but 
the enzyme is also present in the intestines, placenta, kidneys, and leukocytes (Iba K et al. 
2004). Specific ALP isoenzymes to identify the tissue source can be determined after 
fractionation and heat inactivation, but these procedures are not widely available in clinical 
laboratories. Bone-specific ALP (b-ALP) is measured with an immunoradiometric assay. 
Elevated levels of t-ALP are generally due to an abnormal liver function, an increased bone 
activity, or bone metastases. Levels are normally higher in children with growing bones 
than in adults, and often are increased after fracture. In addition, t-ALP and b-ALP can be 
elevated in both primary and secondary HPT, osteomalacia, and in the presence of bone 
metastasis and Paget’s disease. In patients with CKD–MBD alkaline phosphatise may be 
used as an adjunct test, but if values are high, then liver function tests should be checked. t-
ALP could reasonably be used as a routine test to follow response to therapy. The more 
expensive testing for b-ALP can be used when the clinical situation is more ambiguous. 
Testing for t-ALP is inexpensive and therefore may be helpful for following patients’ 
response to therapy or determining bone turnover status when the interpretation of PTH is 
unclear. The use of b-ALP, an indicator of bone source, may provide additional and more 
specific information, although it is not readily available (Iba K et al. 2004).  
3. CKD – MBD and bone abnormalities 
Disorders of mineral metabolism are also associated with abnormal bone structure. It has 
been shown that the gold standard test for bone quality is its ability to resist fracture under 
strain. In animal models, this resistance can be directly tested with three-point bending 
mechanical tests. Bone quality is impaired in CKD, as the prevalence of hip fracture is 
increased in dialysis patients compared with the general population in all age groups. 
Dialysis patients in their forties have a relative risk of hip fracture that is 80-fold higher than 
that of age-matched and sex-matched control subjects. Furthermore, hip fracture in dialysis 
patients is associated with a doubling of the mortality observed in hip fractures in 
nondialysis patients (Coco M and Rush H., 2000; Alem et al., 2000). It has been shown that 
risk factors for hip fracture in CKD patients include age, gender, duration of dialysis, and 
presence of peripheral vascular disease. There are also analyses that found race, gender, 
duration of dialysis, and low or very high PTH levels as risk factors for hip fracture. It has 
been reported that both hip and lumbar-spine fractures occur independent of gender and 
race in CKD patients. Other risk factors for abnormal bone identified in studies from the 
general population are also common in CKD, including smoking, sedentary lifestyle, and 
hypogonadism (Alem et al., 2000). These factors are likely to increase the risk of bone 
fragility and fractures in CKD but have not been well evaluated. Extremes of bone turnover 
found in patients with CKD have significant impact on fragility and are likely additive to 
bone abnormalities commonly found in the aging and sedentary general population 
(Vassalotti et al., 2008; Melamed et al., 2008). 
3.1 Classification of renal osteodystrophy by bone biopsy 
Bone biopsy is performed to understand the pathophysiology and course of bone disease, to 
relate histological findings to clinical symptoms of pain and fracture, and to determine 
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whether treatments are effective. The traditional types of renal osteodystrophy have been 
defined on the basis of turnover and mineralization as follows: mild, slight increase in 
turnover and normal mineralization; osteitis fibrosa, increased turnover and normal 
mineralization; osteomalacia, decreased turnover and abnormal mineralization; adynamic, 
decreased turnover and acellularity; mixed, increased turnover with abnormal 
mineralization. It has been suggested recently that by performing bone biopsies in patients 
with CKD the most important parameters which should be determined are bone turnover, 
bone mineralization, and bone volume (TMV) (Moe et al., 2009).  
3.1.1 Bone turnover  
In CKD patients a spectrum of bone formation rates varies from abnormally low to very 
high. Other measurements that help to define a low or high turnover (such as eroded 
surfaces, number of osteoclasts, fibrosis, or woven bone) tend to be associated with the 
bone-formation rate as measured by tetracycline labeling. This is the most definite dynamic 
measurement, hence it was chosen to represent bone turnover. It should be noted that an 
improvement of a bone biopsy cannot be determined on the basis of a simple change in the 
bone-formation rate, because the restoration of normal bone may require either an increase 
or a decrease in bone turnover, depending on the starting point (Melsen and Moselkilde, 
1978). 
3.1.2 Bone mineralization  
It is a parameter which reflects the amount of unmineralized osteoid. Mineralization is 
measured by the osteoid maturation time or by mineralization lag time, both of which 
depend heavily on the osteoid width as well as on the distance between tetracycline labels. 
The classic disease with an abnormality of mineralization is osteomalacia, in which the 
bone-formation rate is low and the osteoid volume is high. Some patients have a modest 
increase in osteoid, which is a result of high bone formation rates. They do not have 
osteomalacia because the mineralization lag time remains normal. The overall 
mineralization, however, is not normal because unmineralized osteoid is increased.  
3.1.3 Bone volume  
Bone volume contributes to bone fragility and is separate from the other parameters. The 
bone volume is the end result of changes in bone-formation and resorption rates: if the 
overall bone formation rate is higher than the overall bone resorption rate, the bone is in 
positive balance and the bone volume will increase. If mineralization remains constant, an 
increase in bone volume would also result in an increase in BMD and should be detectable 
by dual-energy X-ray absorptiometry (DXA). Although both cortical and cancellous bone 
volumes decrease in typical idiopathic osteoporosis, these compartments are frequently 
different in patients with CKD. In dialysis patients with high PTH levels, the cortical bone 
volume is decreased but the cancellous volume is increased. (Lindergard et al., 1985). 
3.2 Bone markers 
Generally, two different types of bone markers are used to determine the bone 
patophysiology:  
www.intechopen.com
 
Chronic Kidney Disease 
 
32
3.2.1 Collagen based bone markers 
Active osteoblasts secrete pro-collagen type I, and the pro-peptides at both C-terminal and 
N-terminal ends are immediately cleaved and can be measured in the circulation. The 
collagen molecules are then covalently bonded through pyridinoline cross-linking. The 
fragments containing these pyridinoline links (at both the C-terminal  and N-terminal ends 
of the peptides) are released during bone resorption: carboxyterminal (CTX) and 
aminoterminal (NTX) cross-linking telopeptide of bone collagen, respectively. These 
collagen-based markers have been studied in normal populations, where there are 
significant but moderate correlations with bone-formation/resorption rates. These markers 
are usually increased after bone fracture (Ureña and De Vernejoul, 1999; Ivaska et al., 2007).  
3.2.2 Non collagen type of bone markers 
Osteoblasts secrete other proteins that have been used to assess their function, including b-
ALP, osteocalcin, osteoprotegerin, and receptor activator for nuclear factor kB ligand. 
Osteoclasts secrete tartrate-resistant acid phosphatase. Osteocytes secrete FGF-23 in 
response to phosphate and calcitriol. High levels of FGF-23 are seen in patients with CKD, 
but this is a new measurement, and clinical significance remains to be determined. Some of 
these markers are excreted by the kidneys, so in CKD, the serum concentrations may merely 
represent accumulation instead of bone turnover (Rogers and Eastell, 2005). 
Renal phosphate excretion is physiologically regulated mainly by proximal tubular cells, 
which express Na/Pi Type II cotransporters at their apical membrane that control 
phosphate reclamation. Renal phosphate reabsorption is mediated primarily through the 
Na/Pi IIa co-transporter, whereas approximately one-third of phosphate ions are 
reabsorbed through the Na/Pi IIc cotransporter. FGF-23 mediates its phosphaturic effect by 
reducing the abundance of the Na/Pi IIa cotransporter in proximal tubular cells (Baum et al., 
2005). In animal studies, transgenic mice over-expressing human or mouse FGF-23 have 
severe renal phosphate wasting because of suppression of renal Na/Pi cotransporter activity, 
whereas FGF-23 inactivation leads to hyperphosphatemia (Liu et al., 2006). In addition, FGF-
23 may inhibit gastrointestinal phosphate absorption by reducing intestinal Na/Pi IIb 
cotransporter activity in a vitamin D dependent manner (Liu et al., 2006). In CKD patients, 
circulating FGF-23 levels gradually increase with renal function declining. Although the 
increase in FGF-23 is most pronounced in patients with advanced CKD, it may begin at a 
very early stage. Apparently, FGF-23 and PTH stimulate phosphaturia in a similar manner 
by reducing phosphate reclamation through Na/Pi IIa cotransporters. Nonetheless, PTH is 
not indispensable for FGF-23 activity, as the phosphaturic effects of FGF-23 are maintained 
in animals after parathyroidectomy (Liu et al., 2006). In CKD patients, the increase in FGF-23 
starts with modestly impaired estimated glomerular filtration rate, when serum phosphate 
levels are still within the normal range CKD (KDOQI stages 2–3), whereas FGF-23 levels 
increase by more than 100-fold in advanced CKD (KDOQI stage 5) compared with healthy 
controls (Imanishi et al., 2004). However, this is inconsistent with the observation that there 
is no increase in the accumulation of degraded FGF-23 in advanced CKD. These data instead 
favor a mechanism involving increased FGF-23 secretion as the cause of elevated FGF-23 
levels. Instead of decreased renal clearance, an end organ resistance to the phosphaturic 
stimulus of FGF-23 may exist because of a deficiency of the necessary Klotho cofactor 
(Kurosu et al., 2006). Moreover, higher FGF-23 levels in CKD may reflect a physiological  
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compensation to stabilize serum phosphate levels as the number of intact nephrons declines. 
As a result, FGF-23 increases urinary phosphate excretion and decreases gastrointestinal 
phosphate absorption directly and through inhibition of 1a-hydroxylase and reduction of 
circulating calcitriol levels indirectly. Oversecretion of FGF-23 allows the body to maintain 
phosphate levels within a ‘physiological’ range until very advanced CKD stages (Miyamoto 
K et al. 2004).  
4. CKD – MBD – and vascular calcification 
Tissue calcification is a complex and highly regulated process in bone and teeth, and also at 
extraosseous sites. The most threatening localization of unwanted calcification is at vascular 
sites, where it may manifest as both medial and intimal calcification of arteries. Studies in 
the general population have identified calcification in most of atherosclerotic plaques. 
Calcification seems to be a part of the natural development of atherosclerotic plaques, with 
extensive calcification associated with late-stage atherosclerosis. In the general population, 
atherosclerotic plaque calcification is associated with cardiovascular events such as 
myocardial infarction, symptomatic angina pectoris, and stroke. Medial calcification causes 
arterial stiffness, resulting in an elevated pulse pressure and increased pulse wave velocity, 
thereby contributing to left ventricular hypertrophy, dysfunction, and heart failure. 
Furthermore, an advanced calcification of the heart valves may lead to dysfunction 
contributing to heart failure and a risk of endocarditis development (Vliegenthart et al. 2002; 
Vliegenthart et al. 2002).    
4.1 Different types of vascular calcification 
It is generally well recognized that the prevalence of calcification increases with progressively 
decreasing kidney function and is greater than that in the general population. Cardiovascular 
calcification is associated with increased frequency of major cardiovascular diseases, and could 
be of predictive importance for adverse clinical outcomes, including cardiovascular events and 
death (Foley RN et al., 1998). There is an increased prevalence of cardiovascular calcification in 
patients even at early stages of CKD. Thus, an important percentage of CKD patients are at 
high risk of cardiovascular events from vascular calcification. Two patterns of vascular 
calcification have been described: namely intimal and medial calcification. In the general 
population, an elevated coronary artery calcium (CAC) score almost exclusively reflects the 
atherosclerotic disease burden. In two small autopsy studies, it became apparent that, in 
dialysis patients, CAC is also predominantly localized in the coronary intima, whereas the 
medial calcifications observed in a minority of such patients seemed to be adjacent to plaque 
areas just beneath the internal elastic lamina. Although the coronary vascular bed may differ 
considerably from other arteries with regard to the calcification process and its manifestations, 
the same group observed a ‘pure’ medial calcification in the coronary arteries during the early 
stages of CKD (Schwarz et al., 2000). A ‘pure’ medial calcification, in the absence of intimal 
disease, was also observed in epigastric arteries obtained from dialysis patients at the time of 
renal transplantation (Amann K., 2008;).    
4.2 Promoters and inhibitors of calcification 
Vascular calcification is the result of passive and active processes, as is bone mineralization. 
It has been shown that that normal extracellular phosphate concentration is required for 
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bone mineralization, while lowering this concentration prevents mineralization of any 
extracellular matrix. However, simply raising extracellular phosphate concentration is not 
sufficient to induce pathological mineralization, because of the presence in all extracellular 
matrices of pyrophosphate, an inhibitor of mineralization (Riser et al., 2011). They further 
showed that extracellular matrix mineralization normally occurs only in bone because of the 
exclusive coexpression in osteoblasts of Type I collagen and of tissue non-specific alkaline 
phosphatase (Tnap), an enzyme that cleaves pyrophosphate. Pyrophosphate probably is the 
most important non-protein inhibitor of vascular calcification. Its extracellular concentration 
is strictly regulated by several enzymes. It is generated by PC-1 nucleotide triphosphate 
pyrophosphohydrolase and metabolized to inorganic phosphate by nucleotide 
pyrophosphatase/phosphodiesterase (NPP1), in addition to Tnap. Its hydrolysis to 
inorganic phosphate actually transforms it from a calcification inhibitor to a promoter. In 
addition to pyrophosphate other inhibitors are also present locally in VSMCs, including 
matrix-gla protein (MGP) and Smad6 proteine (Lomashvili et al., 2008; Rutsch et al., 2001; 
Johnson et al., 2005).  
4.3 Contribution of experimental models in vascular calcification  
Arterial calcification assessed by all the available imaging studies cannot accurately 
differentiate calcification that is localized to the intima from calcification in the media 
adjacent to the internal elastic lamina, or in the medial layer (Figure 1 and 2). Thus, there is 
neither definitive evidence to suggest that isolated medial calcification is distinct from the 
calcification that occurs in the natural history of atherosclerosis nor is there definite proof 
against it. Experimental and ex vivo studies suggest that the vascular smooth muscle cell 
may be critical in the development of calcification by transforming into an osteoblast-like 
phenotype (Giachelli CM, 2004). Elevated phosphorus, elevated calcium, oxidized low-
density lipoprotein cholesterol, cytokines, and elevated glucose, among others, stimulate 
this transformation of vascular smooth muscle cells into osteoblast-like cells in vitro using 
cell-culture techniques. These factors likely interact at the patient level to increase and/or 
accelerate calcification in CKD. Given the potential complexity of the pathogenesis and the 
inability of radiological techniques to differentiate the location of calcification, the approach 
to all patients with calcification should be to minimize atherosclerotic risk factors and 
control biochemical parameters of CKD–MBD.  In addition, the pericyte in the media and 
adventitia may have a role in the secretion of vascular calcification-inducing factors 
(Giachelli et al., 2004). The stimulus for such a transformation may depend on the location of 
calcification within the artery wall (Figure 2A and 2B). For example, in intimal lesions, 
atherosclerosis may be the most important stimulus. However, in patients with CKD and 
medial calcification, there may be additional, or additive, factors potentially explaining why 
medial calcification of the peripheral arteries can be seen without intimal changes and is 
more common in CKD than in the non-CKD population (Moe et al., 2003).  
Over the past decade, several animal studies have provided evidence for an accelerated 
progression of atherosclerosis in association with the uremic state. We and others have used 
the apolipoprotein e knockout (Apoe–/–) mouse with superimposed CKD and observed that 
in this experimental model of severe hypercholesterolemia the development of 
atheromatous lesions was greatly enhanced compared with the rate of lesion development 
in nonuremic Apoe–/– mice (Massy et al., 2005; Ivanovski et al., 2005). Additionally, in our  
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Fig. 1A. Intima and media calcification by radiography. a) Femoral artery intimal 
calcification; b) Femoral artery medial calcification; c) Pelvic artery medial calcification; d) 
Iliac arteries mixed calcification. (London et al. 2003).  
 
 
Fig. 1B. Coronary artery calcification by Electron beam computed tomography (EBCT), (scan 
courtesy of Pr P. Raggi). 
a) 
c) 
b) 
d) 
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A 
 
B 
Fig. 2. Localization of different types of vascular calcification in humans. A) Intimal; B) 
Medial; (London et al. 2003). 
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model, accelerated calcification of the aortic wall both in the intima and the media, (Figure 
3A and 3B, respectively) occurred in the absence of hypertension, and fetuin a deficiency 
greatly enhanced intimal calcification. Similar observations have been made using another 
hyper cholesterolemic animal model of severe atherosclerosis with superimposed CKD, 
namely the LDL receptor knockout mouse model (Mathew et al. 2007; Davies et al. 2005). Of 
note, the first cardiovascular changes observed in early stages of CKD in Apoe–/– mice as 
well as in wild type mice were left ventricular hypertrophy, altered left ventricular 
relaxation and increased aortic stiffness in the absence of identifiable morphological changes 
of the vessel wall. The observed cardiac and aortic abnormalities were not associated with 
the degree of aortic calcification or the level of serum total cholesterol, but with the extent of 
subendothelial dysfunction and the severity of CKD. Our findings have revealed that the 
cardio vascular lesions observed in early stage of acute kidney injury are likely functional. 
Although the above experimental findings need to be confirmed by additional studies in the 
clinical setting, they open up the possibility of attenuation of atherosclerosis and even 
reversal by adequate therapeutic strategies. Findings from experimental observations favor 
the existence of two different types of vascular disease linked to CKD, namely early 
arteriosclerosis, in the absence of atherosclerosis, and the acceleration of already existing or 
subsequently developing atherosclerosis by the uremic state (Drueke and Massy, 2010).  
Finally, a rare but very severe form of medial calcification of small (cutaneous) arteries is 
calciphylaxis, also called calcific uremic arteriolopathy. This complication is strongly 
associated with CKD-related disturbances of mineral metabolism, including secondary HPT, 
in approximately one-third of cases. It is characterized by ischemic, painful skin ulcerations 
followed by superinfections, and is associated with high mortality. Relationships with 
dysregulated calcification inhibitors (fetuin-A and matrix Gla protein) have been implicated 
in the pathogenesis of calciphylaxis (Schoppet et al., 2008; Suliman et al., 2008), but because 
of the relatively low incidence of the disease, no conclusive data are available to firmly 
comment on the nature of the disease process or to allow generalizable treatment options to 
be recommended. 
4.4 Management of patients with vascular/valvular calcification  
Recently it has been confirmed that cardiovascular calcification development and 
progression can be influenced by treatment. Given that vascular calcification is associated 
with increased cardiovascular risk, and that the pathogenesis seems to be related to CKD–
MBD abnormalities and atherosclerosis, it is appropriate to evaluate and modify both. CKD–
MBD longitudinal studies have also shown that the progression of vascular calcification to 
be modifiable by the choice of phosphate binders. Aluminum-containing phosphate binders 
have been widely abandoned because of serious adverse effects including adynamic bone 
disease, microcytic anemia, dementia, and death (Alfrey et al., 1976). They were initially 
replaced by calcium-containing, aluminum-free phosphate binders. Subsequently, several 
studies showed that the high amounts of calcium ingested with these binders were 
associated with vascular calcification whose progression could be slowed by the calcium-
free, aluminum-free binder sevelamer (Block et al., 2005; Chertow et al., 2002; London et al., 
2008). The Treat-to-Goal study compared sevelamer-HCl to calcium-containing phosphate 
binders, analyzing the progression of coronary artery and aortic calcification (by EBCT) in 
prevalent HD patients over 1 year. Although calcification scores progressed with calcium- 
www.intechopen.com
 
Chronic Kidney Disease 
 
38
 
(a) 
 
(b) 
Fig. 3. Extent and localization of different types of atherosclerotic lesion calcification in 
apoE−/− mice with CRF. von Kossa staining. a) solid type of plaque calcification, 
magnification ×25; b) non-plaque calcification, magnification×25. (Phan et al. 2008).  
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containing phosphate binders, treatment with sevelamer-HCl was associated with a lack of 
calcification progression (Chertow et al., 2002). A similar design was used, and the results 
showed more calcification progression in patients treated with calcium based binders 
compared with sevelamer-HCl in the Renagel in New Dialysis Patients study, which studied 
incident HD patients who were randomized within 90 days after starting dialysis treatment 
(Block et al., 2005). The Calcium Acetate Renagel Evaluation-2 study showed that the use of 
sevelamer-HCl and calcium acetate was associated with equal progression of CAC when 
statins were used to achieve a similar control of the serum low-density lipoprotein 
cholesterol in the two study arms (Qunibi et al., 2008). Interestingly, in Calcium Acetate 
Renagel Evaluation-2, the combination of sevelamer- HCl and atorvastatin was actually 
associated with a higher progression rate of CAC than that in Treat-to-Goal, instead of 
showing an amelioration of CAC progression with the combination of calcium acetate and 
statin. It is difficult to reconcile these differences, although one potential explanation is that 
the Calcium Acetate Renagel Evaluation- 2 study patient population had a higher number of 
cardiovascular risk factors than did that of the Treat-to-Goal study (Floege J., 2008).  
Although abnormalities of calcium phosphate homeostasis have long been linked with 
dysfunction of large arteries in these patients, more recent studies have suggested a role in 
the pathogenesis of atherosclerosis in smaller, critical arteries, most notably the coronary 
arteries (London et al., 2003). Coronary artery calcification (CAC) is a strong predictor of 
atherosclerotic disease in the general population. It has been recognized that most 
population studies measuring CAC did not necessarily exclude individuals on the basis of 
kidney function and thus include variable numbers of CKD patients. In general, this 
literature evaluating the general population supports the view that CAC is part of the 
development of atherosclerosis and occurs almost exclusively together with atherosclerosis 
in human arteries. It seems that calcification occurs early in the atherosclerotic process; 
however, the amount of calcification per lesion has a variable relationship with the 
associated severity of luminal stenosis. The relationship between the degree of calcification 
in an individual lesion and the probability of plaque rupture is unknown. In the general 
population, the overall coronary calcium score can be considered as a measure of the overall 
burden of coronary atherosclerosis. The American College of Cardiology/American Heart 
Association document indicates that the relationship between CAC and cardiovascular 
events in the CKD population is less clear than that in the non-CKD population because of a 
relative lack of informative studies and the possibility that medial calcification may not be 
indicative of atherosclerotic disease severity. The almost exclusive relationship between 
magnitude of calcification and atherosclerosis burden is controversial in CKD patients 
(Amann, 2008), in contrast to the situation in the general population. Antiatherosclerotic 
strategies using statin treatment have been shown to have a beneficial impact on the 
atherogenic profile, atheroma progression, and cardiovascular events in patients with no 
known CKD (Nissen et al. 2004). In our experimental model, we have shown that statins had 
a beneficial effect on uremia enhanced vascular calcification in apoE knock out mice with 
chronic kidney disease. This effect was observed despite the absence of changes in uremia 
accelerated atherosclerosis progression, serum total cholesterol levels or osteopontin and 
alkaline phosphatase expression. This observation opened the possibility of a cholesterol 
independent action of statins on vascular calcification via a decrease in oxidative stress 
(Ivanovski et al., 2008). In CKD patients, there are no data on the effects of statins on arterial  
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calcification, as compared with those of placebo. Even worse, the 4D study failed to show a 
benefit of atorvastatin treatment on the outcome of diabetic dialysis patients. Studies in 
progress like SHARP (Study of Heart and Renal Protection) and AURORA (A Study to 
Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of 
Survival and Cardiovascular Events) failed to show a better understanding of the benefits of 
correcting atherosclerotic risk factors on cardiovascular events and mortality in patients 
with CKD stages 3–5 and 5D (Baigent  et al., 2003).  
An association of vascular calcification with high phosphate intake has so far not been 
directly demonstrated in uremic patients, probably owing to the fact that it is difficult, if not 
impossible, to assess phosphate (protein) intake in a quantitative manner over prolonged 
time periods. Indirect evidence for a role of oral phosphate, however, has recently been 
provided by Russo et al (Russo et al., 2007). They showed that in patients with CKD stage 3-
5, coronary artery calcification score progressed significantly over a time period of 2 years, 
in association with a significant increase in phosphaturia. Many pharmaco-epidemiologic 
studies have shown a survival benefit in CKD patients receiving active vitamin D 
derivatives, as compared to those who did not receive such treatments. Finally, let us not 
forget that association does not imply causation. We clearly need randomized prospective 
trials showing that active reduction of serum phosphorus, PTH, or alkaline phosphatases 
and normalization of serum calcium leads to an improvement in patient outcomes, and that 
specific treatments given to the patients improve outcome, as compared to either placebo or 
other treatments (Drueke and McCarron, 2003). 
To date, there are no published prospective studies in humans that have evaluated the 
impact of calcimimetics or calcitriol and vitamin D analogs on arterial calcification. 
However, a recent observational study showed a U-curve type of relationship between 
serum 1,25(OH)2D3 and arterial calcification in children and adolescents with CKD stage 
5D. No such association existed between serum 25(OH)D and arterial calcification. In one 
study in adult patients with CKD stage 5, no independent association of serum 25(OH)D or 
1,25(OH)2D3 levels with arterial calcification was observed, (London et al., 2007). Although 
the authors of another report identified an association between 25(OH)D deficiency and the 
magnitude of vascular calcification (Matias et al., 2009). The experimental data supporting 
less toxicity of vitamin D analogs compared with calcitriol are not completely consistent 
across studies, but, in general, support the claim that there is reduced calcification with 
equivalent PTH lowering with different vitamin D analogs (Lopez et al., 2008). Experimental 
studies showed differential effects of calcimimetics and calcitriol on extraosseous 
calcification, the former being neutral or protective, the latter being a dose-dependent risk 
factor for calcification.  In our studies, we have analysed the role of chronic renal failure 
(CRF) on the arterial wall changes including atherosclerosis and vascular calcifications in 
CRF apoE-/- mice experimental model (Massy, Ivanovski et al. 2005). Furthermore, we have 
studied the effect of different non-calcium (Phan et al., 2005) and calcium phosphate binders 
(Phan et al., 2008) and role of control of phosphatemia on vascular calcification and 
atherosclerosis (Ivanovski et al. 2009). We have also showed for the first time that the 
phosphate binder La carbonate is capable of preventing both uremia-enhanced vascular 
calcification and atherosclerosis in experimental model of CKD (Nikolov et al., 2011). These 
effects were comparable to those of sevelamer on vascular calcification and atherosclerosis, 
as previously reported by us for sevelamer-HCl in this model (Phan et al., 2008).  
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5. CKD – MBD summary 
Mineral and bone disorders are complex abnormalities that cause morbidity and decreased 
quality of life in patients with CKD. To enhance communication and facilitate research, a 
new term has been established, CKD–Mineral and Bone Disorder (CKD-MBD), to describe 
the syndrome of biochemical, bone, and extraskeletal calcification abnormalities that occur 
in patients with CKD. Also, it has been recommended that the term renal osteodystrophy be 
used exclusively to define alterations in bone morphology associated with CKD. The latter 
can be further assessed by histomorphometry, with results reported on the basis of a 
classification system that includes parameters of turnover, mineralization, and volume. The 
international adoption of the proposed uniform terminology, definition, and classification to 
describe these two disorders caused by CKD enhanced communication, facilitated clinical 
decision making, and can promote the evolution of evidence based clinical-practice 
guidelines worldwide. This issue of Advances in CKD further describes the clinical 
manifestations and pathophysiology of CKD-MBD. The optimal management of CKD-MBD 
(Chronic Kidney Disease – Mineral and Bone Disorder) should be achieved without 
increasing the risk of metastatic calcification, including that of blood vessels.  
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